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A new coronavirus, identified in Wuhan, China, has spread globally, infecting millions of 
people and causing significant morbidity and mortality. The pandemic state, declared by the 
World Health Organization on March 11, 2020, transformed the world and made people adapt 
to social distance to control the spread of the virus. The race against time in search of 
therapeutic solutions has become essential, and nanotechnology may be able to make vaccines 
available in record time to stimulate the immunization of individuals. Since the beginning of 
2020, scientists and companies are rapidly advancing to make vaccine candidates available at 
a different rate compared to other pandemics that have existed. This review briefly presents 
the pros and cons of the third generation vaccines, Moderna / NIAID and Pfizer - BioNTech, 
which are in phase 3 tests, based on lipid RNA nanoparticles. Great collaborative efforts are 
being invested so that soon the world population will receive doses of vaccines with proven 
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efficacy and enable increased survival, since the pandemic has already caused many 
irreversible losses. 
Keywords: COVID-19; Coronavirus; Vaccine; Nanomedicine; Nanotechnology. 
 
Resumo 
Um novo coronavírus, identificado em Wuhan, China, se espalhou globalmente, infectando 
milhões de pessoas e causando morbidade e mortalidade significativas. O estado de pandemia, 
declarado pela Organização Mundial da Saúde em 11 de março de 2020, transformou o 
mundo e fez com que as pessoas se adaptassem ao distanciamento social para controlar a 
disseminação do vírus. A corrida contra o tempo em busca de soluções terapêuticas tornou-se 
imprescindível, e a nanotecnologia pode conseguir disponibilizar vacinas em tempo recorde 
para estimular a imunização dos indivíduos. Desde o início de 2020, os cientistas e empresas 
estão avançando rapidamente para disponibilizar vacinas candidatas num ritmo diferenciado 
comparado a outras pandemias que existiram. Esta revisão apresenta, brevemente, os prós e 
contras das vacinas de terceira geração, Moderna / NIAID e Pfizer - BioNTech, que estão em 
testes de fase 3, com base em nanopartículas de RNA lipídico. Grandes esforços colaborativos 
estão sendo investidos para que em breve a população mundial receba doses de vacinas com 
eficácia comprovada e possibilite o aumento da sobrevida, visto que a pandemia já ocasionou 
muitas perdas irreversíveis. 
Palavras-chave: COVID-19; Coronavírus; Vacina; Nanomedicina; Nanotecnologia. 
 
Resumen 
Un nuevo coronavirus, identificado en Wuhan, China, se ha propagado a nivel mundial, 
infectando a millones de personas y provocando una morbilidad y mortalidad significativas. 
El estado pandémico, declarado por la Organización Mundial de la Salud el 11 de marzo de 
2020, transformó el mundo e hizo que las personas se adaptaran a la distancia social para 
controlar la propagación del virus. La carrera contrarreloj en busca de soluciones terapéuticas 
se ha vuelto fundamental, y la nanotecnología puede hacer que las vacunas estén disponibles 
en un tiempo récord para estimular la inmunización de los individuos. Desde principios de 
2020, los científicos y las empresas están avanzando rápidamente para que los candidatos a 
vacunas estén disponibles a un ritmo diferente en comparación con otras pandemias que han 
existido. Esta revisión presenta brevemente los pros y los contras de las vacunas de tercera 
generación, Moderna / NIAID y Pfizer - BioNTech, que se encuentran en pruebas de fase 3, 
basadas en nanopartículas de ARN lipídico. Se están invirtiendo grandes esfuerzos de 
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colaboración para que pronto la población mundial reciba dosis de vacunas de probada 
eficacia y permitan una mayor supervivencia, ya que la pandemia ya ha provocado muchas 
pérdidas irreversibles. 




In December 2019 an outbreak of an unknown disease emerged in Wuhan, China, it 
was later discovered that it was caused by a new coronavirus, which was named SARS-COV-
2 and, consequently, could cause coronavirus disease (COVID -19), responsible for causing 
the World Health Organization (WHO) to declare a new outbreak pandemic on March 11, 
2020, after the disease had spread intercontinentally (Cucinotta & Vanelli, 2020) 
There have been several attempts to find an effective treatment against COVID-19 
since then, however most of the results have been discouraging and other controversial. Even 
unveiling some mechanisms involving COVID-19, the scenario is still quite challenging 
(Pacheco et al., 2020). 
However, after a year of anxious waiting, agony and millions of deaths from 
coronavirus disease, phase 3 experiments on some vaccines have finally been completed. We 
highlight here mainly the vaccine from Pfizer – BioNTech and Moderna/NIAID, both using a 
lipid nanoparticle platform carrying the virus RNA. These vaccines revolutionized the world, 
first because they are the first third generation vaccines widely accepted, with results released 
in record time, and which promise to change the world pandemic scenario (Campos et al., 
2020; Mahase, 2020b). 
There are dozens of vaccines using nanoparticles in their methodology some using 
nanometric viruses or other nanoparticles. However, here we bring a comparison between the 
results of the most advanced third generation RNA lipid nanoparticle vaccines from 
Moderna/NIAID and Pfizer – BioNTech, with pros and cons, in addition to the challenges 
facing a pandemic that is not over yet, but which already sheds light on the end of the tunnel 
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Studies published in PubMed, Scielo, and Google Scholar databases. According to the 
indexes of the various databases, search terms were used: “nanovaccines”, “COVID-19”, 
“Moderna/NIAID”, “Pfizer – BioNTech” without any language restrictions. 
 




The Moderna/NIAID vaccine (mRNA-1273) works with mRNA, encapsulated by lipid 
nanoparticles (Figure 1), capable of encoding the coronavirus Spike protein and causing host 
cells to produce anti-Spike protein immune responses. This vaccine is administered in two 
doses, at an interval of 0-28 days, has an efficiency of 94.5% and is easily stored (-20ºC) 




The Pfizer-Biotech vaccine is based on a modified virus mRNA platform carried by 
lipid nanoparticles (Figure 1). Initially Pfizer-BioNTech had released results of the 
BNT162b1 vaccine (which encodes for the S receptor-binding domain), however due to the 
better safety profile results of BNT162b2 (encoding for SARS-CoV-2 full-length S, stabilized 
in the prefusion conformation), this was chosen for phase 3 tests and achieved an efficiency of 
95% (Mahase, 2020a; Mulligan et al., 2020; Polack et al., n.d.; Walsh et al., 2020) (Table 1). 
This vaccine was first approved in the United Kingdom (UK), but despite having one of 
the best vaccine efficacies against COVID-19, has a limitation that can be a barrier for 
countries without structure: the vaccine has to be stored at temperatures below -70ºC 
(Mahase, 2020a) (Table 1). 
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Figure 1. Mechanism of RNA lipid nanoparticle vaccines from Moderna/NIAID and Pfizer- 
BioNTech. Lipid nanoparticles carrying mRNA coding spike protein that triggering immune 
response in host cells. 
 
Source: Authors (2020). 
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Table 1. Comparison of Nano Vaccines candidates Moderna and Pfizer-BioNTech. 
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Unlike vaccines with live or attenuated virus, RNA vaccines allow, for example, 
pregnant and immunocompromised women to take the vaccine, in addition to being a much 
faster alternative in production, when compared to traditional vaccines (Sahin et al., 2014). 
Thanks to this technology, the long-awaited phase 3 vaccines have finally been 
completed, giving much hope to humanity in challenges with the COVID-19 pandemic. But 
there are still some questions that need to be answered: when will the entire world population 
have access to these and other vaccines against COVID-19? Will low income countries be 
able to buy vaccines? How long will these vaccines give an effective immune response? Will 
they be able to prevent the transmission of the virus? These and many other questions may be 
answered soon. But in the meantime, the vaccine must be applied in all possible ways, to 
mitigate the damage caused by this terrible disease (Mahase, 2020b). 
However, it is unquestionable that the world has changed the way of producing 
vaccines, a process that would take years, which lasted about a year (Kim et al., 2020). Shi et 
al (2010) already stated that nanotechnology would revolutionize the world, and, in fact, 
changed in this pandemic. Thanks to mRNA technology vaccine and nanomedicine we can 




About one year after the emergence of the new coronavirus (SARS-COV-2), phase 3 
trials of innovative third generation vaccines were completed in record time, with the help of 
nanomedicine. Although Pfizer – BioNTech's nano vaccine is 95% effective and approved in 
the United Kingdom, it has logistical problems, as it needs a temperature below -70º to be 
stored, making it difficult to use in many countries. On the other hand, Moderna/NIAID nano 
vaccine has an efficiency of 94.5% and can be stored in conventional freezers (-20º), 
facilitating its use in several countries. Nanomedicine helped revolutionize history, in the 
battle against COVID-19, by producing 3rd generation vaccines, using lipid nanoparticles 
carrying RNA. For the first time in history, we will have vaccines of RNA with lipid 
nanoparticles approved and saving millions of lives. 
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